Expert opinion on available options treating pulmonary arterial hypertension (Q36967262)

17 August 2017

1 reference

title

Expert opinion on available options treating pulmonary arterial hypertension (English)

1 reference

17 August 2017

Robert Naeije

1

1 reference

PubMed ID

17927481

17 August 2017

Sandrine Huez

series ordinal

2

1 reference

PubMed ID

17927481

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

14

1 reference

17 August 2017

2247-2265

1 reference

Treatment of pulmonary arterial hypertension

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Medical therapy of pulmonary hypertension. Conventional therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Nocturnal oxygen therapy in patients with the Eisenmenger syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Aspects of prostaglandin function in the lung (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Treprostinil for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Identical twins with primary pulmonary hypertension: beraprost vs epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Bosentan therapy for portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Effects of long-term bosentan in children with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil: A 4-year update in the treatment of 20 million erectile dysfunction patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Phosphodiesterase type 5 and high altitude pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil for pulmonary arterial hypertension: when blue turns into white

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil treatment for portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Sildenafil for pulmonary arterial hypertension: still waiting for evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Emerging therapies for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Rho-kinase inhibitors show promise in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Increased plasma serotonin in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Simvastatin treatment of pulmonary hypertension: an observational case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Atrial septostomy for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2247

10.1517/14656566.8.14.2247

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17927481